Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural […]
Drug-Device Combinations
Kala Pharmaceuticals slides on missed Q4 projections
Kala Pharmaceuticals (NSDQ:KALA) shares dipped this morning on fourth-quarter results that came up short of the consensus forecast. The Watertown, Mass.-based company posted losses of -$31.1 million, or -55¢ per share, on sales of $2.2 million for the three months ended Dec. 31, 2020, for a more than $10 million bottom-line slide on sales growth of […]
Tandem Diabetes Care skyrockets after hours on Street-beating Q4
Tandem Diabetes Care (NSDQ:TNDM) shares soared after hours today on fourth-quarter results that topped the consensus forecast. Shares of TNDM were up 12.9% at $103.04 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%. Get the full story at our sister site, […]
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]
B. Braun Medical appoints new CFO
B. Braun Medical announced today that it appointed James Allen as a senior VP and as the company’s chief financial officer. Allen, a veteran of more than 30 years in finance and management within multiple industries and disciplines, will replace Bruce Heugel, who last year announced that he would retire after more than 20 years […]
Re-Vana Therapeutics appoints new COO, VP of R&D
Re-Vana Therapeutics announced today that it appointed Michael Nash as chief commercial officer and David Shima as VP of R&D. Belfast, Northern Ireland-based Re-Vana’s two new executives are set to help the company develop its sustained-release therapies for ophthalmic indications, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and glaucoma, according to a news […]
Pear Therapeutics touts cost-effectiveness of opioid use disorder treatment
Pear Therapeutics today touted analysis of its reSET-O therapeutic for opioid use disorder (OUD) that demonstrated cost-effectiveness. Boston-based Pear Therapeutics’ reSET-O is the first and only FDA-authorized prescription digital therapeutic for treating OUD, according to a news release. Get the full story at our sister site, Drug Delivery Business News.
AmacaThera raises $10.3M in oversubscribed Series A
AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round. Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according to […]
Acorda Therapeutics announces departure of business operations chief
Acorda Therapeutics (NSDQ:ACOR) announced today that its chief of business operations, David Lawrence, is resigning from the company. Lawrence, who also serves as Acorda’s principal accounting and financial officer, is resigning effective mid-March 2021 as he is set to take a leadership position at an early-stage biotechnology company, according to a news release. Get the full […]
Lyra Therapeutics names new chief medical officer
Lyra Therapeutics (NSDQ:LYRA) announced today that it appointed Dr. Robert Kern as its new chief medical officer. Kern will remain in his current position as the George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery at the Northwestern University Feinberg School of Medicine while operating as Lyra’s CMO, according to a […]
Retractable Technologies lands $54.2M federal contract for syringes
Retractable Technologies (NYSE:RVP) announced that it received a government contract worth more than $54.2 million for its syringes. Little Elm, Texas-based Retractable Technologies’ contract and purchase order was made by the U.S. Health & Human Services Dept. (HHS) with a base price of $54,217,800 for a five-month period between Feb. 15, 2021, and July 14, 2021. […]